Skip to content

Structure-first design of a photoswitchable JAK2 inhibitor candidate with isomer-selective binding.

Aug 2026 · Computational biology and chemistry · Vol 125, pp. 109335 · 0 citations · 45 references
Medicine

TL;DR

This work establishes a generalizable in silico framework for designing photoswitchable kinase inhibitor candidates with built-in functional asymmetry, highlighting the potential of computational approaches to guide photopharmacological ligand design.

Abstract

Precise control over kinase inhibitor selectivity and activity remains a central challenge in targeted drug design. While photopharmacology offers a route to modulate ligand activity with light, most implementations rely on azologization of existing scaffolds which limits the rational tuning of the structure-function relationships. Here, we present a de novo computational design strategy for a photoswitchable inhibitor candidate of Janus kinase 2 (JAK2), integrating molecular docking, molecular dynamics simulations, and binding free energy analysis to encode isomer-dependent affinity at the design stage. The resulting candidate ligand, IPTA, incorporates a photoresponsive core directly into the ligand architecture to achieve differential binding between its (E)- and (Z)-isomers. The (E)-isomer is predicted to form stable interactions with key regions of the JAK2 active site, including the hinge and xDFG motifs, whereas the (Z)-isomer exhibits reduced affinity due to steric incompatibility and loss of critical contacts. The free energy calculations predict a reversible, isomer-selective binding mechanism. Therefore, our work establishes a generalizable in silico framework for designing photoswitchable kinase inhibitor candidates with built-in functional asymmetry, highlighting the potential of computational approaches to guide photopharmacological ligand design.

View source

Similar papers

Open access Sep 2026

Thinking Outside the Binding Site: A Self-Encapsulating Kinase Inhibitor Remodels Its Pocket to Achieve Selectivity.

Rendering kinase inhibitors selective is a strict requirement in drug development and remains a persistent challenge. To identify new routes to engineer selectivity, we have discovered a first-in-class p38δ-isoform selective inhibitor reflecting 12 000-fold selectivity improvement over currently available compounds and...

Nico J. Seidler, Monica R. MacDonald, Athina A. Moschopoulou et al. · 0 citations
Open access Sep 2026

Dissecting affinity determinants of benzotriazine-based ligands at sigma-1 receptor: a multilevel molecular dynamics analysis.

The sigma-1 receptor (S1R) is a chaperone protein involved in several physiological and pathological processes and represents an attractive target for the development of neuroactive and anticancer agents. Among S1R ligands, 3,3-disubstituted 3,4-dihydro-1,2,4-benzotriazines constitute a pharmacologically relevant but m...

M. Tonelli, Valeria Francesconi, Bruno Tasso et al. · 0 citations
Review Open access Aug 2026

Adventures in Chemical Space: From Targets to Drugs to Design Principles.

The central theme, conformational analysis, links on-target potency via pre-organization of the bioactive conformation with physics-based physicochemical property prediction with physics-based physicochemical property prediction, highlighting neutral polarity as a key determinant of permeability and exposure.

H. Möbitz · 0 citations
Open access Aug 2026

Dissecting the binding landscape of four cKIT inhibitors through an integrated multifaceted approach.

This work highlights how distinct inhibitors exploit different conformational states of cKIT and demonstrates the value of integrating structural analyses, biophysical measurements, calculations and molecular simulations to define the mechanism of kinase inhibition.

Irene Cipollone, Carmen Gratteri, C. Talarico et al. · 0 citations
Open access Aug 2026

PAM-DB: Revealing Protein Activation Mechanisms for Next-Generation Rational Drug Discovery

A structural database that systematically maps the complete activation trajectories of pharmaceutically relevant targets, encompassing TS, IS, and all connecting conformational ensembles is presented, offering multiple strategic advantages for drug discovery.

Xiaohong Zhu, Xiangyu Li, Yaning Hou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.